<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559116</url>
  </required_header>
  <id_info>
    <org_study_id>1237.20</org_study_id>
    <secondary_id>2011-004710-42</secondary_id>
    <nct_id>NCT01559116</nct_id>
  </id_info>
  <brief_title>Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg, 5/5 µg), Tiotropium (2.5 µg, 5 µg) and Olodaterol (5 µg) (Oral Inhalation, Delivered by the Respimat® Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD) [VIVACITOTM]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to determine the 24-hour FEV1-time profile of
      tiotropium + olodaterol FDC, administered once daily by the RESPIMAT Inhaler after 6 weeks of
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) AUC0-24h Response [L] After 6 Weeks Treatment.</measure>
    <time_frame>day 1 and week 6</time_frame>
    <description>Area under the Forced Expiratory Volume in 1 second (FEV1) after 6 weeks treatement-time curve from 0 to 24 h post-dose, using the trapezoidal rule, divided by the duration (24 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean and standard error (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-12h Response [L] After 6 Weeks Treatment.</measure>
    <time_frame>day 1 and week 6</time_frame>
    <description>Area under the Forced Expiratory Volume in 1 second (FEV1) after 6 weeks treatement-time curve from 0 to 12 h post-dose, using the trapezoidal rule, divided by the duration (12h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC12-24h Response [L] After 6 Weeks Treatment.</measure>
    <time_frame>day 1 and week 6</time_frame>
    <description>Area under the Forced Expiratory Volume in 1 second (FEV1) after 6 weeks treatement-time curve from 12 to 24 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response [L] After 6 Weeks Treatment.</measure>
    <time_frame>day 1 and week 6</time_frame>
    <description>Trough Forced Expiratory Volume in 1 second (FEV1) response after 6 weeks treatment period.
The trough was defined as the mean of the 23 h and 23 h50 min measurements and Response was defined as the change from patient baseline.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak(0-3h) FEV1 Response [L] After 6 Weeks Treatment.</measure>
    <time_frame>day 1 and week 6</time_frame>
    <description>Peak (0-3h) Forced Expiratory Volume in 1 second (FEV1) response.
The peak was defined as the maximum value measured within the first 3 h post dosing and response was defined as the change from patient baseline.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC0-24h Response [L] After 6 Weeks Treatment.</measure>
    <time_frame>day 1 and week 6</time_frame>
    <description>Area under the Forced Vital Capacity (FVC) after 6 weeks treatment period-time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC0-12h Response [L] After 6 Weeks Treatment.</measure>
    <time_frame>day 1 and week 6</time_frame>
    <description>Area under the Forced Vital Capacity (FVC) after 6 weeks treatment period-time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC12-24h Response [L] After 6 Weeks Treatment.</measure>
    <time_frame>day 1 and week 6</time_frame>
    <description>Area under the Forced Vital Capacity (FVC) after 6 weeks treatment period-time curve from 12 to 24 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response [L] After 6 Weeks Treatment.</measure>
    <time_frame>day1 and week 6</time_frame>
    <description>Trough Forced Vital Capacity (FVC) response after 6 weeks treatment period.
The trough was defined as the mean of the 23 h and 23 h50 min measurements and response was defined as the change from patient baseline.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak (0-3h) FVC Response [L] After 6 Weeks Treatment.</measure>
    <time_frame>day 1 and week 6</time_frame>
    <description>Peak (0-3h) Forced Vital Capacity (FVC) responses after 6 weeks treatment.
Peak was defined as the maximum value measured within the first 3 h post dosing and response was defined as the change from patient baseline.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>tiotropium+olodaterol FDC low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium+olodaterol FDC high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tiotropium low dose; 2 inhalations once daily (a.m. dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tiotropium high dose; 2 inhalations once daily (a.m. dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olodaterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one dose only; 2 inhalations once daily (a.m. dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 inhalations once daily (a.m. dosing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium + olodaterol</intervention_name>
    <description>low dose + one dose only</description>
    <arm_group_label>tiotropium+olodaterol FDC high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>low dose</description>
    <arm_group_label>tiotropium low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olodaterol</intervention_name>
    <description>one dose only</description>
    <arm_group_label>olodaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>high dose</description>
    <arm_group_label>tiotropium high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium + olodaterol</intervention_name>
    <description>low dose + one dose only</description>
    <arm_group_label>tiotropium+olodaterol FDC low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo matching tiotropium+olodaterol FDC</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>Respimat inhaler</description>
    <arm_group_label>tiotropium+olodaterol FDC low dose</arm_group_label>
    <arm_group_label>tiotropium+olodaterol FDC high dose</arm_group_label>
    <arm_group_label>tiotropium low dose</arm_group_label>
    <arm_group_label>tiotropium high dose</arm_group_label>
    <arm_group_label>olodaterol</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of chronic obstructive pulmonary disease

          2. Relatively stable airway obstruction with a post-bronchodilator FEV1&lt; 80% of predicted
             normal and a post-bronchodilator FEV1/FVC &lt;70%

          3. Male or female patients, 40 years of age or older

          4. Smoking history of more than 10 pack years

          5. Ability to perform technically acceptable pulmonary function tests and maintain
             records

          6. Ability to inhale medication in a competent manner from the RESPIMAT Inhaler and from
             a metered dose inhaler (MDI)

        Exclusion criteria:

          1. significant disease other than COPD

          2. clinically relevant abnormal lab values

          3. history of asthma

          4. diagnosis of thyrotoxicosis

          5. diagnosis of paroxysmal tachycardia

          6. history of myocardial infarction

          7. unstable or life-threatening cardiac arrhythmia

          8. Hospitalization for heart failure within the past year

          9. known active tuberculosis

         10. malignancy for which patient has undergone resection, radiation therapy or
             chemotherapy within last five years

         11. history of life-threatening pulmonary obstruction

         12. history of cystic fibrosis

         13. clinically evident bronchiectasis

         14. history of significant alcohol or drug abuse

         15. history of thoracotomy with pulmonary resection

         16. oral or patch ß-adrenergics

         17. oral corticosteroid medication at unstable doses

         18. regular use daytime oxygen therapy for more than one hour per day

         19. Pulmonary rehabilitation program in the six weeks prior to the screening visit

         20. Investigational drug within one month or six half lives (whichever is greater) prior
             to screening visit

         21. Known hypersensitivity to ß-adrenergic drugs, BAC, EDTA

         22. Pregnant or nursing women

         23. Women of childbearing potential not using a highly effective method of birth control

         24. Patients who have previously been randomised in this study or are currently
             participating in another study

         25. Patients who are unable to comply with pulmonary medication restrictions prior to
             randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1237.20.1204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.1203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.1201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.1202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.32203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.32201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.32204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jambes</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.02201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.02202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.49205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.49204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.49203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.49206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.49201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.49207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mönchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.49202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.36202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gödöllö</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.36204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komarom</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.36203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.36201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szarvas</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.36205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szazhalombatta</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.31205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.31202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.31201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.31204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.20.31203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zutphen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2012</study_first_posted>
  <results_first_submitted>June 19, 2015</results_first_submitted>
  <results_first_submitted_qc>June 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2015</results_first_posted>
  <disposition_first_submitted>April 3, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 3, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 30, 2014</disposition_first_posted>
  <last_update_submitted>June 19, 2015</last_update_submitted>
  <last_update_submitted_qc>June 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This is a randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over design. Each patient was randomised to one of 30 treatment sequences. Each sequence consisted of four 6-week treatment periods separated by 3-week washout periods.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Subjects</title>
          <description>Randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over trial to characterise the 24-hour lung function profiles of tiotropium + olodaterol fixed dose combination (2.5/5 μg, 5/5 μg), tiotropium (2.5 μg, 5 μg) and olodaterol (5 μg) (oral inhalation, delivered by the Respimat® Inhaler) after 6 weeks once daily treatment in patients with Chronic Obstructive Pulmonary Disease (COPD) [VIVACITOTM].</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="219">Randomised</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="193">Completed all 4 treatment periods</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other than stated above</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): This patient set includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>Randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over trial to characterise the 24-hour lung function profiles of tiotropium + olodaterol fixed dose combination (2.5/5 μg, 5/5 μg), tiotropium (2.5 μg, 5 μg) and olodaterol (5 μg) (oral inhalation, delivered by the Respimat® Inhaler) after 6 weeks once daily treatment in patients with Chronic Obstructive Pulmonary Disease (COPD) [VIVACITOTM].</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) AUC0-24h Response [L] After 6 Weeks Treatment.</title>
        <description>Area under the Forced Expiratory Volume in 1 second (FEV1) after 6 weeks treatement-time curve from 0 to 24 h post-dose, using the trapezoidal rule, divided by the duration (24 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean and standard error (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
        <time_frame>day 1 and week 6</time_frame>
        <population>Full Analysis Set (FAS): This patient set included patients in the Treated Set (TS) who had any period baseline and any evaluable post-dose data for the primary efficacy endpoint at any Week 6 visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching Tiotropium+Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT:2 Oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (5 µg)</title>
            <description>Olodaterol solution for inhalation - RESPIMAT
2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (2.5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium (5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium+Olodaterol FDC (2.5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium+Olodaterol FDC (5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) AUC0-24h Response [L] After 6 Weeks Treatment.</title>
          <description>Area under the Forced Expiratory Volume in 1 second (FEV1) after 6 weeks treatement-time curve from 0 to 24 h post-dose, using the trapezoidal rule, divided by the duration (24 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean and standard error (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
          <population>Full Analysis Set (FAS): This patient set included patients in the Treated Set (TS) who had any period baseline and any evaluable post-dose data for the primary efficacy endpoint at any Week 6 visits.</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.037" spread="0.014"/>
                    <measurement group_id="O2" value="0.129" spread="0.013"/>
                    <measurement group_id="O3" value="0.117" spread="0.013"/>
                    <measurement group_id="O4" value="0.133" spread="0.014"/>
                    <measurement group_id="O5" value="0.241" spread="0.014"/>
                    <measurement group_id="O6" value="0.244" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.280</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.252</ci_lower_limit>
            <ci_upper_limit>0.309</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.115</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.087</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.082</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.277</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.249</ci_lower_limit>
            <ci_upper_limit>0.306</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.083</ci_lower_limit>
            <ci_upper_limit>0.140</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.124</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium low dose (2.5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.107</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.079</ci_lower_limit>
            <ci_upper_limit>0.136</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC0-12h Response [L] After 6 Weeks Treatment.</title>
        <description>Area under the Forced Expiratory Volume in 1 second (FEV1) after 6 weeks treatement-time curve from 0 to 12 h post-dose, using the trapezoidal rule, divided by the duration (12h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
        <time_frame>day 1 and week 6</time_frame>
        <population>Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching Tiotropium+Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 Oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (5 µg)</title>
            <description>Olodaterol solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (2.5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium (5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium+Olodaterol FDC (2.5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium+Olodaterol FDC (5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-12h Response [L] After 6 Weeks Treatment.</title>
          <description>Area under the Forced Expiratory Volume in 1 second (FEV1) after 6 weeks treatement-time curve from 0 to 12 h post-dose, using the trapezoidal rule, divided by the duration (12h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
          <population>Full Analysis Set (FAS).</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.013" spread="0.015"/>
                    <measurement group_id="O2" value="0.179" spread="0.015"/>
                    <measurement group_id="O3" value="0.171" spread="0.015"/>
                    <measurement group_id="O4" value="0.186" spread="0.015"/>
                    <measurement group_id="O5" value="0.310" spread="0.015"/>
                    <measurement group_id="O6" value="0.305" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.319</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.289</ci_lower_limit>
            <ci_upper_limit>0.349</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.156</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.119</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.089</ci_lower_limit>
            <ci_upper_limit>0.149</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.323</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.293</ci_lower_limit>
            <ci_upper_limit>0.354</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.131</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.101</ci_lower_limit>
            <ci_upper_limit>0.161</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.139</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.109</ci_lower_limit>
            <ci_upper_limit>0.169</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium low dose (2.5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.124</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.093</ci_lower_limit>
            <ci_upper_limit>0.154</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC12-24h Response [L] After 6 Weeks Treatment.</title>
        <description>Area under the Forced Expiratory Volume in 1 second (FEV1) after 6 weeks treatement-time curve from 12 to 24 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
        <time_frame>day 1 and week 6</time_frame>
        <population>Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching Tiotropium+Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 Oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (5 µg)</title>
            <description>Olodaterol solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (2.5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium (5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium+Olodaterol FDC (2.5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium+Olodaterol FDC (5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC12-24h Response [L] After 6 Weeks Treatment.</title>
          <description>Area under the Forced Expiratory Volume in 1 second (FEV1) after 6 weeks treatement-time curve from 12 to 24 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
          <population>Full Analysis Set (FAS).</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.060" spread="0.014"/>
                    <measurement group_id="O2" value="0.079" spread="0.013"/>
                    <measurement group_id="O3" value="0.062" spread="0.013"/>
                    <measurement group_id="O4" value="0.081" spread="0.014"/>
                    <measurement group_id="O5" value="0.172" spread="0.014"/>
                    <measurement group_id="O6" value="0.182" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.243</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.212</ci_lower_limit>
            <ci_upper_limit>0.273</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.133</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.102</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.232</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.201</ci_lower_limit>
            <ci_upper_limit>0.262</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.093</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.063</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.080</ci_lower_limit>
            <ci_upper_limit>0.140</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium low dose (2.5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.091</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.061</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response [L] After 6 Weeks Treatment.</title>
        <description>Trough Forced Expiratory Volume in 1 second (FEV1) response after 6 weeks treatment period.
The trough was defined as the mean of the 23 h and 23 h50 min measurements and Response was defined as the change from patient baseline.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
        <time_frame>day 1 and week 6</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching Tiotropium+Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 Oral inhalations once daily in the morning for 6 weeks.)</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (5 µg)</title>
            <description>Olodaterol solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (2.5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium (5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium+Olodaterol FDC (2.5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium+Olodaterol FDC (5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response [L] After 6 Weeks Treatment.</title>
          <description>Trough Forced Expiratory Volume in 1 second (FEV1) response after 6 weeks treatment period.
The trough was defined as the mean of the 23 h and 23 h50 min measurements and Response was defined as the change from patient baseline.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
          <population>Full Analysis Set (FAS)</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.015"/>
                    <measurement group_id="O2" value="0.109" spread="0.015"/>
                    <measurement group_id="O3" value="0.095" spread="0.015"/>
                    <measurement group_id="O4" value="0.122" spread="0.015"/>
                    <measurement group_id="O5" value="0.196" spread="0.015"/>
                    <measurement group_id="O6" value="0.201" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.207</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.173</ci_lower_limit>
            <ci_upper_limit>0.241</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.092</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.126</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.201</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.167</ci_lower_limit>
            <ci_upper_limit>0.235</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.052</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.101</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.067</ci_lower_limit>
            <ci_upper_limit>0.135</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium low dose (2.5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.073</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.107</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak(0-3h) FEV1 Response [L] After 6 Weeks Treatment.</title>
        <description>Peak (0-3h) Forced Expiratory Volume in 1 second (FEV1) response.
The peak was defined as the maximum value measured within the first 3 h post dosing and response was defined as the change from patient baseline.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
        <time_frame>day 1 and week 6</time_frame>
        <population>Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching Tiotropium+Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 Oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (5 µg)</title>
            <description>Olodaterol solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (2.5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium (5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium+Olodaterol FDC (2.5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium+Olodaterol FDC (5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak(0-3h) FEV1 Response [L] After 6 Weeks Treatment.</title>
          <description>Peak (0-3h) Forced Expiratory Volume in 1 second (FEV1) response.
The peak was defined as the maximum value measured within the first 3 h post dosing and response was defined as the change from patient baseline.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
          <population>Full Analysis Set (FAS).</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="137"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.072" spread="0.017"/>
                    <measurement group_id="O2" value="0.291" spread="0.016"/>
                    <measurement group_id="O3" value="0.290" spread="0.016"/>
                    <measurement group_id="O4" value="0.300" spread="0.016"/>
                    <measurement group_id="O5" value="0.422" spread="0.016"/>
                    <measurement group_id="O6" value="0.411" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.338</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.305</ci_lower_limit>
            <ci_upper_limit>0.371</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.120</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.087</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.078</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.350</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.317</ci_lower_limit>
            <ci_upper_limit>0.383</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.131</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.164</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.099</ci_lower_limit>
            <ci_upper_limit>0.165</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium low dose (2.5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.122</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.089</ci_lower_limit>
            <ci_upper_limit>0.155</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC0-24h Response [L] After 6 Weeks Treatment.</title>
        <description>Area under the Forced Vital Capacity (FVC) after 6 weeks treatment period-time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
        <time_frame>day 1 and week 6</time_frame>
        <population>Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching Tiotropium+Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 Oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (5 µg)</title>
            <description>Olodaterol solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (2.5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium (5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium+Olodaterol FDC (2.5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium+Olodaterol FDC (5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC0-24h Response [L] After 6 Weeks Treatment.</title>
          <description>Area under the Forced Vital Capacity (FVC) after 6 weeks treatment period-time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
          <population>Full Analysis Set (FAS).</population>
          <units>Litres(L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.065" spread="0.023"/>
                    <measurement group_id="O2" value="0.158" spread="0.022"/>
                    <measurement group_id="O3" value="0.172" spread="0.022"/>
                    <measurement group_id="O4" value="0.191" spread="0.022"/>
                    <measurement group_id="O5" value="0.331" spread="0.022"/>
                    <measurement group_id="O6" value="0.368" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.433</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.389</ci_lower_limit>
            <ci_upper_limit>0.477</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.210</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.166</ci_lower_limit>
            <ci_upper_limit>0.253</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.177</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.133</ci_lower_limit>
            <ci_upper_limit>0.221</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.396</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.352</ci_lower_limit>
            <ci_upper_limit>0.441</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.173</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.129</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.159</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.115</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium low dose (2.5 µg) is calculated. is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.140</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.184</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC0-12h Response [L] After 6 Weeks Treatment.</title>
        <description>Area under the Forced Vital Capacity (FVC) after 6 weeks treatment period-time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
        <time_frame>day 1 and week 6</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching Tiotropium+Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 Oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (5 µg)</title>
            <description>Olodaterol solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (2.5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium (5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium+Olodaterol FDC (2.5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium+Olodaterol FDC (5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC0-12h Response [L] After 6 Weeks Treatment.</title>
          <description>Area under the Forced Vital Capacity (FVC) after 6 weeks treatment period-time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
          <population>Full Analysis Set (FAS)</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.023" spread="0.024"/>
                    <measurement group_id="O2" value="0.240" spread="0.024"/>
                    <measurement group_id="O3" value="0.249" spread="0.024"/>
                    <measurement group_id="O4" value="0.261" spread="0.024"/>
                    <measurement group_id="O5" value="0.420" spread="0.024"/>
                    <measurement group_id="O6" value="0.440" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.463</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.417</ci_lower_limit>
            <ci_upper_limit>0.509</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.200</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.154</ci_lower_limit>
            <ci_upper_limit>0.246</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.179</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.133</ci_lower_limit>
            <ci_upper_limit>0.225</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.443</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.396</ci_lower_limit>
            <ci_upper_limit>0.490</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.181</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.134</ci_lower_limit>
            <ci_upper_limit>0.227</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.171</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.125</ci_lower_limit>
            <ci_upper_limit>0.218</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium low dose (2.5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.159</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.024</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.113</ci_lower_limit>
            <ci_upper_limit>0.206</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC12-24h Response [L] After 6 Weeks Treatment.</title>
        <description>Area under the Forced Vital Capacity (FVC) after 6 weeks treatment period-time curve from 12 to 24 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
        <time_frame>day 1 and week 6</time_frame>
        <population>Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching Tiotropium+Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 Oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (5 µg)</title>
            <description>Olodaterol solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (2.5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium (5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium+Olodaterol FDC (2.5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium+Olodaterol FDC (5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC12-24h Response [L] After 6 Weeks Treatment.</title>
          <description>Area under the Forced Vital Capacity (FVC) after 6 weeks treatment period-time curve from 12 to 24 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
          <population>Full Analysis Set (FAS).</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.108" spread="0.023"/>
                    <measurement group_id="O2" value="0.077" spread="0.023"/>
                    <measurement group_id="O3" value="0.095" spread="0.023"/>
                    <measurement group_id="O4" value="0.122" spread="0.023"/>
                    <measurement group_id="O5" value="0.243" spread="0.023"/>
                    <measurement group_id="O6" value="0.296" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.404</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.355</ci_lower_limit>
            <ci_upper_limit>0.453</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.219</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.170</ci_lower_limit>
            <ci_upper_limit>0.267</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.174</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.126</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.351</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.301</ci_lower_limit>
            <ci_upper_limit>0.400</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.117</ci_lower_limit>
            <ci_upper_limit>0.214</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.148</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.099</ci_lower_limit>
            <ci_upper_limit>0.197</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium low dose (2.5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response [L] After 6 Weeks Treatment.</title>
        <description>Trough Forced Vital Capacity (FVC) response after 6 weeks treatment period.
The trough was defined as the mean of the 23 h and 23 h50 min measurements and response was defined as the change from patient baseline.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
        <time_frame>day1 and week 6</time_frame>
        <population>Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching Tiotropium+Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 Oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (5 µg)</title>
            <description>Olodaterol solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (2.5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium (5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium+Olodaterol FDC (2.5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium+Olodaterol FDC (5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response [L] After 6 Weeks Treatment.</title>
          <description>Trough Forced Vital Capacity (FVC) response after 6 weeks treatment period.
The trough was defined as the mean of the 23 h and 23 h50 min measurements and response was defined as the change from patient baseline.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
          <population>Full Analysis Set (FAS).</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.025" spread="0.026"/>
                    <measurement group_id="O2" value="0.134" spread="0.026"/>
                    <measurement group_id="O3" value="0.115" spread="0.026"/>
                    <measurement group_id="O4" value="0.183" spread="0.026"/>
                    <measurement group_id="O5" value="0.282" spread="0.026"/>
                    <measurement group_id="O6" value="0.304" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.329</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.274</ci_lower_limit>
            <ci_upper_limit>0.385</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.170</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.115</ci_lower_limit>
            <ci_upper_limit>0.225</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.066</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.307</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.029</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.251</ci_lower_limit>
            <ci_upper_limit>0.363</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.092</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.111</ci_lower_limit>
            <ci_upper_limit>0.222</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium low dose (2.5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.043</ci_lower_limit>
            <ci_upper_limit>0.154</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak (0-3h) FVC Response [L] After 6 Weeks Treatment.</title>
        <description>Peak (0-3h) Forced Vital Capacity (FVC) responses after 6 weeks treatment.
Peak was defined as the maximum value measured within the first 3 h post dosing and response was defined as the change from patient baseline.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
        <time_frame>day 1 and week 6</time_frame>
        <population>Full Analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching Tiotropium+Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 Oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Olodaterol (5 µg)</title>
            <description>Olodaterol solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (2.5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Tiotropium (5 µg)</title>
            <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Tiotropium+Olodaterol FDC (2.5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Tiotropium+Olodaterol FDC (5/5 µg)</title>
            <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak (0-3h) FVC Response [L] After 6 Weeks Treatment.</title>
          <description>Peak (0-3h) Forced Vital Capacity (FVC) responses after 6 weeks treatment.
Peak was defined as the maximum value measured within the first 3 h post dosing and response was defined as the change from patient baseline.
Mean is actually the Adjusted mean.
The adjusted mean (SE) are obtained from fitting a mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; period baseline and patient baseline as covariates; patient as a random effect; compound symmetry covariance structure for within−patient variation and Kenward−Roger approximation of denominator degrees of freedom.</description>
          <population>Full Analysis Set (FAS)</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="136"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="135"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.159" spread="0.029"/>
                    <measurement group_id="O2" value="0.463" spread="0.029"/>
                    <measurement group_id="O3" value="0.450" spread="0.029"/>
                    <measurement group_id="O4" value="0.470" spread="0.029"/>
                    <measurement group_id="O5" value="0.612" spread="0.029"/>
                    <measurement group_id="O6" value="0.621" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.462</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.408</ci_lower_limit>
            <ci_upper_limit>0.516</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.159</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.105</ci_lower_limit>
            <ci_upper_limit>0.212</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.151</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.205</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.452</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.398</ci_lower_limit>
            <ci_upper_limit>0.507</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Placebo is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.149</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.095</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Olodaterol (5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.161</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.107</ci_lower_limit>
            <ci_upper_limit>0.216</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium low dose (2.5 µg) is calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effect model repeated measures (MMRM) with fixed effects for treatment,period and random effect for patient.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.142</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.087</ci_lower_limit>
            <ci_upper_limit>0.196</ci_upper_limit>
            <estimate_desc>Adjusted mean difference to Tiotropium high dose (5 µg) is calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From drug administration until 21 days after the last administration, upto 92 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo matching Tiotropium+Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 Oral inhalations once daily in the morning for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Olodaterol (5 µg)</title>
          <description>Olodaterol solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Tiotropium (2.5 µg)</title>
          <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Tiotropium (5 µg)</title>
          <description>Tiotropium solution for inhalation - RESPIMAT : 2 oral inhalations once daily in the morning for 6 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Tiotropium+Olodaterol FDC (2.5/5 µg)</title>
          <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Tiotropium+Olodaterol FDC (5/5 µg)</title>
          <description>Tiotropium + Olodaterol fixed dose combination (FDC) solution for inhalation – RESPIMAT: 2 oral inhalations once daily in the morning for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="139"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="139"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

